Dr Dorene Anne O'hara, MD | |
1734 Seagull Ct, Apt. 402, Reston, VA 20194-4307 | |
(732) 423-8533 | |
(571) 313-0523 |
Full Name | Dr Dorene Anne O'hara |
---|---|
Gender | Female |
Speciality | Clinic/center - Ambulatory Surgical |
Location | 1734 Seagull Ct, Reston, Virginia |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1679656607 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207L00000X | Anesthesiology | 048518 (New Jersey) | Secondary |
261QA1903X | Clinic/center - Ambulatory Surgical | 0101240686 (Virginia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Dorene Anne O'hara, MD 1734 Seagull Ct, Apt. 402, Reston, VA 20194-4307 Ph: (732) 423-8533 | Dr Dorene Anne O'hara, MD 1734 Seagull Ct, Apt. 402, Reston, VA 20194-4307 Ph: (732) 423-8533 |
News Archive
Humans and mice have previously unknown and potentially critical differences in one of the genes responsible for Duchenne muscular dystrophy (DMD). Researchers writing in the open access journal BMC Biology have found that two major features of a key DMD gene are present in most mammals, including humans, but are specifically absent in mice and rats, calling into question the use of the mouse as the principal model animal for studying DMD.
Medical imaging has long been a vital tool for the diagnosis and prognostic assessments of many diseases. In recent years, the use of artificial intelligence models has been used in conjunction with this imaging to augment their diagnostic capabilities.
AIDS Healthcare Foundation (AHF) has sent a letter dated October 20, 2004, to the heads of all state Medicaid programs asking them put in use treatment authorization request (TAR) procedures on GlaxoSmithKline's (GSK) fixed-dose combination AIDS drug, Trizivir, as a standalone regimen for treatment naïve patients.
Maxygen, Inc. today announced that it has been advised by the Biomedical Advanced Research and Development Authority (BARDA) that Maxygen's proposal for the development of its MAXY-G34 product candidate as a potential medical countermeasure for Acute Radiation Syndrome (ARS) will not be considered for a contract award.
› Verified 7 days ago